Antisense Therapeutics Limited Stock Current Liabilities
| ATHJF Stock | USD 0.04 0.00 0.00% |
Antisense Therapeutics Limited fundamentals help investors to digest information that contributes to Antisense Therapeutics' financial success or failures. It also enables traders to predict the movement of Antisense Pink Sheet. The fundamental analysis module provides a way to measure Antisense Therapeutics' intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Antisense Therapeutics pink sheet.
Antisense |
Antisense Therapeutics Limited Company Current Liabilities Analysis
Antisense Therapeutics' Current Liabilities is the company's short term debt. This usually includes obligations that are due within the next 12 months or within one fiscal year. Current liabilities are very important in analyzing a company's financial health as it requires the company to convert some of its current assets into cash.
Current Antisense Therapeutics Current Liabilities | 1000 K |
Most of Antisense Therapeutics' fundamental indicators, such as Current Liabilities, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Antisense Therapeutics Limited is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Current liabilities appear on the company's balance sheet and include all short term debt accounts, accounts and notes payable, accrued liabilities as well as current payments due on the long-term loans. One of the most useful applications of Current Liabilities is the current ratio which is defined as current assets divided by its current liabilities. High current ratios mean that current assets are more than sufficient to pay off current liabilities.
| Competition |
In accordance with the recently published financial statements, Antisense Therapeutics Limited has a Current Liabilities of 1000 K. This is 99.94% lower than that of the Healthcare sector and significantly higher than that of the Drug Manufacturers—Specialty & Generic industry. The current liabilities for all United States stocks is 99.99% higher than that of the company.
Antisense Current Liabilities Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Antisense Therapeutics' direct or indirect competition against its Current Liabilities to detect undervalued stocks with similar characteristics or determine the pink sheets which would be a good addition to a portfolio. Peer analysis of Antisense Therapeutics could also be used in its relative valuation, which is a method of valuing Antisense Therapeutics by comparing valuation metrics of similar companies.Antisense Therapeutics is currently under evaluation in current liabilities category among its peers.
Antisense Fundamentals
| Return On Equity | -0.43 | |||
| Return On Asset | -0.25 | |||
| Operating Margin | (3.28) % | |||
| Current Valuation | 27.82 M | |||
| Shares Outstanding | 669.04 M | |||
| Shares Owned By Insiders | 19.30 % | |||
| Shares Owned By Institutions | 4.93 % | |||
| Price To Earning | (3.62) X | |||
| Price To Book | 3.05 X | |||
| Price To Sales | 24.46 X | |||
| Revenue | 1.78 M | |||
| Gross Profit | 1.71 M | |||
| EBITDA | (7.52 M) | |||
| Net Income | (5.81 M) | |||
| Cash And Equivalents | 19.23 M | |||
| Cash Per Share | 0.03 X | |||
| Total Debt | 227.4 K | |||
| Debt To Equity | 0.01 % | |||
| Current Ratio | 19.14 X | |||
| Book Value Per Share | 0.03 X | |||
| Cash Flow From Operations | (7.81 M) | |||
| Earnings Per Share | (0.01) X | |||
| Number Of Employees | 12 | |||
| Beta | 0.67 | |||
| Market Capitalization | 41.78 M | |||
| Total Asset | 22.44 M | |||
| Retained Earnings | (53 M) | |||
| Working Capital | 4 M | |||
| Current Asset | 5 M | |||
| Current Liabilities | 1000 K | |||
| Net Asset | 22.44 M |
About Antisense Therapeutics Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Antisense Therapeutics Limited's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Antisense Therapeutics using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Antisense Therapeutics Limited based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Currently Active Assets on Macroaxis
Other Information on Investing in Antisense Pink Sheet
Antisense Therapeutics financial ratios help investors to determine whether Antisense Pink Sheet is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in Antisense with respect to the benefits of owning Antisense Therapeutics security.